Liang et al. developed a nanodroplet-based ultrasound contrast and therapeutic agent (NDsUCA/Tx) that targets tumor vasculature with high CD93 expression, enabling molecular imaging of tumor neovascularization and precise tumor microenvironment remodeling [194]. This evidence concerns the gene CD93 and neoplasm.